Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.94 USD | -1.70% | -4.80% | -21.58% |
May. 07 | Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors | CI |
May. 01 | Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts | MT |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 17.65 | 8.016 | 5.47 | 5.909 | - | - |
Enterprise Value (EV) 1 | 17.65 | 8.016 | 5.47 | 5.909 | 5.909 | 5.909 |
P/E ratio | -0.45 x | -0.31 x | -0.33 x | -0.48 x | -0.63 x | -0.59 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | 21.9 x | - | - | - |
EV / Revenue | - | - | 21.9 x | - | - | - |
EV / EBITDA | - | - | - | - | - | - |
EV / FCF | - | - | - | - | - | - |
FCF Yield | - | - | - | - | - | - |
Price to Book | - | - | - | - | - | - |
Nbr of stocks (in thousands) | 18.1 | 103 | 618 | 851.4 | - | - |
Reference price 2 | 975.0 | 78.00 | 8.850 | 6.940 | 6.940 | 6.940 |
Announcement Date | 3/17/22 | 3/22/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net sales 1 | - | - | 0.25 | - | - | - |
EBITDA | - | - | - | - | - | - |
EBIT 1 | -41.85 | -15.31 | -13.07 | -12.46 | -15.13 | -16.91 |
Operating Margin | - | - | -5,228% | - | - | - |
Earnings before Tax (EBT) 1 | -26.62 | -14.26 | -12.3 | -12.46 | -15.13 | -16.9 |
Net income 1 | -26.62 | -14.26 | -12.3 | -12.46 | -15.13 | -16.9 |
Net margin | - | - | -4,920% | - | - | - |
EPS 2 | -2,145 | -247.9 | -27.00 | -14.40 | -10.95 | -11.85 |
Free Cash Flow | - | - | - | - | - | - |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 3/17/22 | 3/22/23 | 3/26/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 0.25 | - | - | - | - | - | - | - |
EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBIT 1 | -3.016 | -4.027 | -3.888 | -3.572 | -4.003 | -3.848 | -2.529 | -3.609 | -3.778 | -3.154 | -3.161 | -3.037 | -3.097 | -3.159 |
Operating Margin | - | - | - | - | - | - | -1,011.6% | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 8.087 | 1.073 | -4.205 | -2.344 | -3.991 | -3.72 | -2.34 | -3.393 | -3.596 | -2.971 | -3.161 | -3.037 | -3.097 | -3.159 |
Net income 1 | 8.087 | 1.073 | -4.205 | -2.344 | -3.991 | -3.72 | -2.34 | -3.393 | -3.596 | -2.971 | -3.161 | -3.037 | -3.097 | -3.159 |
Net margin | - | - | - | - | - | - | -936% | - | - | - | - | - | - | - |
EPS 2 | 315.0 | 480.0 | -195.0 | -90.00 | -60.00 | -89.85 | -8.100 | -7.950 | -7.350 | -3.750 | -3.750 | -3.600 | -3.600 | -3.450 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 11/12/21 | 3/17/22 | 5/13/22 | 8/15/22 | 11/14/22 | 3/22/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/26/24 | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - |
Free Cash Flow | - | - | - | - | - | - |
ROE (net income / shareholders' equity) | - | - | - | - | - | - |
ROA (Net income/ Total Assets) | - | - | - | - | - | - |
Assets 1 | - | - | - | - | - | - |
Book Value Per Share | - | - | - | - | - | - |
Cash Flow per Share | - | - | - | - | - | - |
Capex | - | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 3/17/22 | 3/22/23 | 3/26/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.58% | 5.91M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- SNCA Stock
- Financials Palisade Bio, Inc.